| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |





From the Department of Pathology*
and the
Division of Gastroenterology,
Department of
Medicine, University of Washington, Seattle; Epoch Pharmaceuticals
Incorporated,
Redmond; and the Department of
Biostatistics,§
Fred Hutchinson Cancer Research
Center, Seattle, Washington
Cyclooxygenase 2 (COX-2) overexpression has been described in sporadic colonic neoplasia, but its role in ulcerative colitis (UC) neoplastic progression remains unexplored. Although the specific role of cyclooxygenase in colonic neoplasia is uncertain, its inhibition by nonsteroidal anti-inflammatory drugs decreases the risk of sporadic colonic adenocarcinoma and causes regression of adenomas in familial adenomatous polyposis. To investigate the role of COX-2 in UC-associated neoplasia, we assessed COX-2 protein and mRNA expression throughout the spectrum of UC-associated neoplastic lesions in four total colectomy specimens, using immunocytochemistry and a novel TaqMan reverse transcriptase-polymerase chain reaction assay. The findings were correlated with DNA ploidy and inflammatory activity. We found COX-2 overexpression throughout the neoplastic spectrum in UC (P < 0.0001, R2=0.53), even in diploid samples that were negative for dysplasia. Overall, neoplastic change explained 53% of the variation in COX-2 expression, whereas inflammatory activity explained only 11%. COX-2 was overexpressed in all aneuploid samples and in 38% of diploid samples (P = 0.0074). cDNA representational difference analysis was also performed and revealed that COX-2 mRNA was an up-regulated cDNA representational difference analysis difference product. COX-2 overexpression occurs early in UC-associated neoplasia, and the increase cannot be explained by inflammatory activity alone. The data suggest that COX-2-specific inhibitors may have a chemopreventative role in UC but the possibility that they could exacerbate UC inflammatory activity needs to be tested.
This article has been cited by other articles:
![]() |
Y. Tao, J. Hart, L. Lichtenstein, L. J. Joseph, M. J. Ciancio, S. Hu, E. B. Chang, and M. Bissonnette Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer Carcinogenesis, January 1, 2009; 30(1): 175 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Khor, M.-T. Huang, A. Prawan, Y. Liu, X. Hao, S. Yu, W. K. L. Cheung, J. Y. Chan, B. S. Reddy, C. S. Yang, et al. Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal Cancer Cancer Prevention Research, August 1, 2008; 1(3): 187 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kohno, R. Suzuki, Y. Yasui, S. Miyamoto, K. Wakabayashi, and T. Tanaka Ursodeoxycholic Acid versus Sulfasalazine in Colitis-Related Colon Carcinogenesis in Mice Clin. Cancer Res., April 15, 2007; 13(8): 2519 - 2525. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Itzkowitz and X. Yio Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |